JAZZ — Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $1.1 billion, a 19% increase year-over-year.
• Non-GAAP Adjusted EPS: $6.34.
• Cash Flow from Operations: Over $400 million.
• Product Performance:
  • Xywav: $408 million in sales (up 18%).
  • Epidiolex: $250 million in sales (up 15%).
  • Zepzelca: $101 million in sales (up 60%).
  • Modeyso: $41 million in sales since launch.
  • Ziihera: $13 million in sales.
• Cash and Investments: $2.9 billion at quarter-end.

2. Strategic Updates and Business Highlights

• Jazz reported strong commercial execution across its portfolio, particularly in sleep, epilepsy, and oncology.
• Zanidatamab: FDA accepted the supplemental BLA for priority review with a PDUFA date of August 25, 2026, for HER2-positive first-line metastatic gastric cancer.
• Epidiolex: Focus on expanding into adult populations and long-term care settings, with initiatives to improve patient persistency.
• Modeyso: Strong launch performance with potential for first-line treatment positioning.
• Continued investment in R&D with multiple ongoing trials across various indications.

3. Forward Guidance and Outlook

• Reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.5 billion.
• Anticipated competitive dynamics in the second half of the year, particularly in the sleep business with the entry of generics and new agents.
• Expectation of continued growth in Xywav and Zepzelca, with potential declines in second-line Zepzelca use due to competition.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Anticipation of increased competition in the sleep segment, particularly from generics and new wake-promoting agents.
• Xywav: Potential headwinds from generics entering the market, with expectations of payer actions as volumes grow.
• Zepzelca: Expected decline in second-line use due to competitive dynamics.
• Market Dynamics: Risks associated with the evolving competitive landscape in oncology and sleep treatments.

5. Notable Q&A Insights

• Zanidatamab in Breast Cancer: The trial will provide critical data for sequencing therapies in HER2-positive patients; Jazz aims to lead with definitive data.
• Modeyso Patient Population: Initial estimates suggest a potential peak opportunity of $500 million in the U.S., with ongoing evaluation of treatment duration and patient population size.
• Epidiolex Growth: Strong performance driven by volume growth and strategic investments in adult patient outreach.
• Xywav's Competitive Landscape: Despite the entry of generics, Xywav has maintained strong patient growth and market presence, supported by unique product benefits and patient services.

Overall, Jazz Pharmaceuticals demonstrated robust financial performance in Q1 2026, with significant growth across its product portfolio and strategic advancements in its pipeline, while also navigating potential competitive challenges ahead.